Novo Nordisk AS (OCSE:NOVO B)
kr 775.8 18.5 (2.44%) Market Cap: 3.45 Til Enterprise Value: 3.43 Til PE Ratio: 36.59 PB Ratio: 28.65 GF Score: 97/100

Novo Nordisk A/S to Discuss Supply Challenges for Wegovy Call Transcript

Dec 20, 2021 / 07:30AM GMT
Release Date Price: kr337.6 (-11.73%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Wegovy Supply Update. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Karsten Knudsen. Please go ahead, sir.

Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

Thank you. Good morning, and welcome to the Novo Nordisk Wegovy Supply Update. My name is Karsten Knudsen, CFO of Novo Nordisk. And with me today, I have Henrik Wulff, EVP of Product Supply.

This meeting follows the company announcement we issued Friday afternoon following a meeting with our contract manufacturing organization updating us on the supply consequences of a cGMP issue they have witnessed.

According to Danish rules, we must immediately disclose such information to the market if deemed material, which we assessed. And following that, we have been assessing the situation and we will now, over the next 30 minutes, provide a status of the Wegovy supply situation based on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot